Clinical trials: Prevention of Ischemic Stroke
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Acenocoumarol for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947985
- Testing
- Rivaroxoban (Xarelto, Bay59-7939), Standard of care
- Where
- Netherlands
- Volunteers
- 208,958 people
- Sponsor
- Bayer
Depression, Acute Ischemic Stroke
Prophylactic Effects of Agomelatine for Poststroke Depression
The incidence of depression in stroke patients with frontal lobe involvement was reported to be as high as 42%. Agomelatin, a type 1/2 melatonin receptor agonist and serotonin 2C receptor antagonist, is effective in treatment of…
- Trial name
- PRAISED (NCT05426304)
- Testing
- Agomelatine
- Volunteers
- 420 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Atherosclerosis, Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis…
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00526474
- Testing
- Vorapaxar
- Volunteers
- 26,449 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia, Hypercholesterolemia
Patient and Provider Assessment of Lipid Management Registry
The purpose of the Patient and Provider Assessment of Lipid Management Registry (PALM) is to gain a better understanding of physicians' cholesterol medication prescribing practices, patient and physician attitudes and beliefs…
- Conditions
- Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes
- Trial name
- PALM (NCT02341664)
- Where
- 14 sites in United States
- Volunteers
- 7,658 people
- Sponsor
- Duke University
Internal Carotid Artery Stenosis
SONOlysis in Prevention of Brain InfaRctions During Internal Carotid Endarterectomy
SONOBIRDIE Trial is a randomized, single-blind, sham-controlled study designed for a demonstration of the safety and effectiveness of sonolysis (continual transcranial Doppler (TCD) monitoring) in reduction of risk of stroke or…
- Trial name
- SONOBIRDIE (NCT02398734)
- Testing
- sonolysis
- Where
- Czechia
- Volunteers
- 1,492 people
- Sponsor
- University Hospital Ostrava
Stroke, Physical Therapy Modality
Effectiveness of Telephysical Therapy as a Secondary Stroke Prevention Tool in Patients With Minor Stroke.
This study investigates the effectiveness of telephysiotherapy as a rehabilitation and secondary prevention tool in patients with minor stroke, TIA, or LACI, comparing an experimental group receiving tele-assisted aerobic and…
- Conditions
- Stroke, Physical Therapy Modality, Secondary Prevention, Physical Therapy Evaluation
- Trial name
- TPT-Stroke (NCT06780891)
- Testing
- Telephysical therapy, Educational session
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- University of Cadiz
Ischemic Attack, Transient, Transient
E-Selectin Nasal Instillation to Prevent Secondary Stroke
This study will determine the maximum safe dose of the experimental drug E-selectin that can be given to stroke patients. E-selectin causes white blood cells called lymphocytes to change so that they prevent clots from forming in…
- Trial name
- NCT00069069
- Testing
- Intransal instillation of E-selectin
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Cardiovascular Diseases, Myocardial Ischemia
Cardio-Cerebrovascular Co-Prevention and Co-Management Based on Internet+
Coronary heart disease and stroke are belong to the atherosclerotic vascular disease (ASCVD). When both occur at the same time, the mortality rate is 19%-37%.
- Conditions
- Cardiovascular Diseases, Myocardial Ischemia, Cerebrovascular Disorders, Stroke
- Trial name
- DEMO-CoCo (NCT04409210)
- Testing
- Establishment of individual health records, Cardiovascular risk assessment, Popularization of medical knowledge
- Where
- China
- Volunteers
- 8,840 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cerebral Infarction
Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke
This study evaluate the effects of acupuncture method on the recurrence of ischemic stroke patients.Half of participants will receive "Huo Xue San Feng" acupuncture combining 1 antihypertensive medication on the routine ischemic…
- Trial name
- NCT02967484
- Testing
- acupuncture
- Where
- 5 sites in China
- Volunteers
- 480 people
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Ischemic Stroke, Transient Ischemic Attack
Stroke-Card Registry
Stroke is the second leading cause of death and one of the main contributors to disability. Patients who survive the acute phase of ischemic stroke and those with transient ischemic attack (TIA) are at high risk of subsequent…
- Trial name
- SCR (NCT04582825)
- Testing
- N/A - Observational Study
- Where
- 2 sites in Austria
- Volunteers
- 5,000 people
- Sponsor
- VASCage GmbH
Ischemic Attack, Transient, Stroke
Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke
This study evaluates the use of Colchicine in adults over 40 years of age who have suffered an ischaemic stroke or transient ischaemic attack NOT caused by cardiac embolism or other defined causes.
- Trial name
- CONVINCE (NCT02898610)
- Testing
- Colchicine
- Where
- 145 sites in Belgium, Canada and 12 more
- Volunteers
- 3,154 people
- Sponsor
- University College Dublin
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation
The purpose of this study are 1) to characterize the primary and secondary prevention patients, 2) to calculate incidence rates of stroke/SE or major bleeding in each cohort and 3) to investigate for Japanese secondary prevention…
- Trial name
- NCT05321810
- Testing
- Apixaban, Warfarin
- Where
- Japan
- Volunteers
- 193,565 people
- Sponsor
- Pfizer
Non-valvular Atrial Fibrillation, Embolic Stroke
Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events
This clinical study is a prospective, multi-center, non-interventional study designed to investigate the safety and effectiveness of percutaneous LAA appendage closure by using LAmbre™ Left Atrial Appendage Occluder System.
- Trial name
- NCT04559243
- Testing
- Transthoracic Echocardiography
- Where
- 5 sites in China
- Volunteers
- 579 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Ischemic Stroke, Intracranial Atherosclerosis
Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)
CATIS-ICAS is a double-blind, randomized, placebo-controlled (RCT), phase III study seeking to demonstrate that oral rivaroxaban 2.5 mg twice daily plus aspirin daily is superior to clopidogrel 75 mg daily plus aspirin daily for…
- Trial name
- CATIS-ICAS (NCT07468448)
- Testing
- Rivaroxaban, ASA
- Volunteers
- 1,172 people
- Sponsor
- Population Health Research Institute
Cerebrovascular Disease
The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease
This study is a prospective, randomized, single-center trial, designed to observe the effect of remote limb ischemic preconditioning on ischemic cerebral vascular disease.
- Trial name
- NCT01321749
- Testing
- Remote ischemic preconditioning (RIPC)
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Capital Medical University
Mini-Stroke
Intensified Secondary Prevention Intending a Reduction of Recurrent Events in TIA and Minor Stroke Patients
Patients after TIA or Stroke are at high risk of experiencing a new stroke or myocardial infarction. Poor adherence to evidence based secondary prevention regimens is frequently seen.
- Trial name
- INSPiRE-TMS (NCT01586702)
- Testing
- Patient centered structured support program
- Where
- Germany
- Volunteers
- 2,082 people
- Sponsor
- Charite University, Berlin, Germany
Coronary Heart Disease, Stroke
Hamburg City Health Study - a German Cohort Study
The Hamburg City Health Study (HCHS) is a large, prospective, long-term, population-based cohort study and a unique research platform and network to obtain substantial knowledge about several risk and prognostic factors in major…
- Conditions
- Coronary Heart Disease, Stroke, Dementia, Cancer
- Trial name
- HCHS (NCT03934957)
- Where
- Germany
- Volunteers
- 45,000 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Ischemic Stroke
Risk Assessment Model for Ischemic Stroke Endpoint Events
The present study aims to develope a risk assessment model of ischemic stroke endpoint events combining multi-dimensional traditional Chinese medicine(TCM) indicators with modern medicine indicators.
- Trial name
- NCT03174535
- Testing
- Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- China Academy of Chinese Medical Sciences
Cardiovascular Diseases, Myocardial Infarction
Real World Evidence Study of Statin Use in Brazil
A cross-sectional real-world data study designed to assess the use of statins in individuals assisted within the primary care system in Brazil.
- Conditions
- Cardiovascular Diseases, Myocardial Infarction, Stroke, Hypertension
- Trial name
- RWE-Statins (NCT05285085)
- Testing
- Statin
- Where
- Brazil
- Volunteers
- 2,133,900 people, healthy volunteers welcome
- Sponsor
- Hospital Israelita Albert Einstein
Brain Infarction, Transient Ischemic Attack
Aortic Arch Related Cerebral Hazard Trial (ARCH)
The ARCH is a controlled trial with a sequential design and with a prospective, randomized, open-label, blinded-endpoint (PROBE) methodology.
- Conditions
- Brain Infarction, Transient Ischemic Attack, Embolism
- Trial name
- ARCH (NCT00235248)
- Testing
- Warfarin, Clopidogrel-aspirin
- Where
- 2 sites in Australia, France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris